Recurrent Verrucous Carcinoma of the Larynx Completed Phase 2 Trials for Lapatinib (DB01259)

Also known as: Laryngeal verrucous carcinoma recurrent / Recurrent Laryngeal Verrucous Carcinoma / Squamous Cell Carcinoma of the Larynx / Laryngeal squamous cell carcinoma / Primary squamous cell carcinoma of larynx (disorder) / Squamous cell carcinoma of larynx (disorder)

IndicationStatusPhase
DBCOND0029506 (Recurrent Verrucous Carcinoma of the Larynx)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01044433Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and NeckTreatment
NCT00114283Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck CancerTreatment